Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis

Table 3 Univariate analysis of prognostic factors for disease-free survival and overall survival in 132 patients with hepatocellular carcinoma

Factor	n	6-yr disease-free survival	P value	6-yr overall survival	P value
NG2			0.000		0.000
Negative	84	15.2%		29.2%
Positive	48	6.7%		9.5%
Age (yr)			0.946		0.356
≥ 50	62	10.2%		21.0%
< 50	70	9.7%		31.4%
Sex			0.281		0.316
Male	106	7.1%		23.6%
Female	26	21.7%		38.5%
Tumor size			0.122		0.116
≥ 5 cm	90	11.8%		28.9%
< 5 cm	42	5.6%		21.4%
TNM stage			0.001		0.003
I, II	52	10.2%		34.6%
III, IV	80	9.7%		21.3%
Differentiation			0.108		0.119
Well	33	23.3%		33.3%
Moderate	52	2.0%		9.6%
Poor	47	9.5%		12.8%
Serum AFP			0.044		0.099
≥ 200 ng/dL	42	2.3%		18.0%
< 200 ng/dL	90	13.6%		14.0%
Invasion			0.000		0.000
Yes	70	7.7%		12.9%
No	62	12.5%		21.0%
Number			0.041		0.057
Multiple	31	10.7%		16.1%
Single	101	9.7%		16.8%
Capsule			0.064		0.055
Yes	58	14.3%		21.6%
No	74	6.2%		32.8%

NG2: Neuron-glia antigen 2; TNM stage: Tumor node metastasis stage.